Review on diagnosis and treatment of focal segmental glomerulosclerosis.
Focal segmental glomerulosclerosis (FSGS) is one the most important causes of the nephrotic syndrome in adult patients. FSGS is not a disease entity. The identification of underlying causes of FSGS (secondary FSGS) has increased our insight into the pathogenesis of FSGS. Moreover, differentiating between primary (idiopathic) and secondary forms of FSGS is important to allow appropriate treatment. Recently a new pathological classification of FSGS was proposed, expanding FSGS to include nonsclerotic lesions. In this review we discuss the current diagnostic and therapeutic options in patients with FSGS.
Deegens
J K J
JK
Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. j.deegens@nier.umcn.nl
Steenbergen
E J
EJ
Wetzels
J F M
JF
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D005923:Glomerulosclerosis, Focal Segmental / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents; D017410:Practice Guidelines as Topic; D011379:Prognosis
D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents